Adaptive Radiotherapy for Genitourinary Cancers
About this study
The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are: Does adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy? Participants will: Undergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion
- Condition
- Prostate Cancer (Post Prostatectomy), Bladder Cancer
- Tested
- adaptive RT
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer (Post Prostatectomy), Bladder Cancer
- Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;
- Age ≥ 18 years;
- ECOG performance status score 0-2;
- No prior radiotherapy history within the current radiation field;
- No contraindications for MRI scanning;
- No contraindications for radiotherapy.
Exclusion 2
- Patients with contraindications to radiotherapy;
- Patients unable to tolerate MRI or with contraindications to MRI scanning.
Where
1 site, 1 recruiting
Cancer Hospital, National Cancer Center, CAMS & PUMC
Beijing, Beijing Municipality, China
Contact
-
Ning-Ning Lu, M.D.
861018611804268 ningninglu09@163.com
Potential match only. Final eligibility is determined by the study team.